A Multi-center, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of Mizoribine in Comparison With Cyclophosphamide in the Treatment of Lupus Nephritis
Phase of Trial: Phase III
Latest Information Update: 10 Jun 2019
Price : $35 *
At a glance
- Drugs Mizoribine (Primary) ; Cyclophosphamide
- Indications Lupus nephritis
- Focus Therapeutic Use
- Sponsors Asahi Kasei
- 05 Jun 2019 Status changed from active, no longer recruiting to completed.
- 05 Apr 2018 Planned End Date changed from 1 Jan 2019 to 1 Mar 2019.
- 05 Apr 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Mar 2019.